Want to join the conversation?
Janssen-Cilag International, a $JNJ company, said a final, following this CHMP positive opinion, decision from the European Commission is expected later this year. Janssen is now seeking approval for ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease in the U.S.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.